Know Cancer

or
forgot password

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma Proved by Laboratory Tests

Thank you

Trial Information

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China


Inclusion Criteria:



- Must be Multiple Myeloma Proved by Laboratory Tests

- Must have the ability to observe the efficacy and events

- Patient must have the ability to understand and willingness to provide written
informed consent in the study and any related procedures being performed

Exclusion Criteria:

- If have uncontrolled intercurrent illness including ongoing or active infection,heart
failure,unstable angina pectoris,or psychiatric illness/social situations that study
requirements

- If have severe side-effects on bortezomib

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall survival rates

Outcome Time Frame:

three years

Safety Issue:

Yes

Principal Investigator

Fu chengcheng, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

First Affiliated Hospital,Soochow University

Authority:

China: Ethics Committee

Study ID:

chengchengfu

NCT ID:

NCT01812096

Start Date:

November 2012

Completion Date:

December 2016

Related Keywords:

  • Multiple Myeloma Proved by Laboratory Tests
  • multiple myeloma
  • bortezomib
  • Subcutaneous
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location